within Pharmacolibrary.Drugs.ATC.V;

model V09CA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 370 / 1000000,
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Technetium (99mTc) gluconate is a radiopharmaceutical agent used in nuclear medicine imaging, primarily for renal imaging and assessment of renal perfusion and function. It is labeled with the metastable nuclear isomer technetium-99m, which emits gamma radiation suitable for detection by gamma cameras. The use of technetium-99m gluconate is well-established for diagnostic imaging, and it remains in clinical use for these purposes.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies specific to technetium (99mTc) gluconate with numerical parameters for PK model identified. Estimated PK parameters are based on related technetium-99m renal radiopharmaceuticals and summary information in clinical literature.</p><h4>References</h4><ol><li><p>Tsoukalas, C, et al., &amp; Chiotellis, E (2003). Novel oxorhenium and oxotechnetium MO(NS)(S)2 complexes in the development of 5-HT1A receptor imaging agents. <i>Journal of inorganic biochemistry</i> 93(3-4) 213â€“220. DOI:<a href=&quot;https://doi.org/10.1016/s0162-0134(02)00574-3&quot;>10.1016/s0162-0134(02)00574-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12576284/&quot;>https://pubmed.ncbi.nlm.nih.gov/12576284</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09CA05;
